{"id": "05eec7a1-67e4-43ce-9b09-da96c5edd46d", "page": 1, "type": "table", "data": [["A BS T R AC T", ""], ["BACKGROUND", ""], ["Quadrivalent recombinant influenza vaccines contain three times the amount of", "From \nthe  Kaiser  Permanente  Vaccine"], ["", "Study Center, Oakland, CA. Dr. Klein can"], ["hemagglutinin protein as standard-dose egg-based vaccines, and the recombinant", ""], ["", "be contacted at nicola.klein@kp.org or at"], ["formulation is not susceptible to antigenic drift during manufacturing. Data are", ""], ["", "the  Kaiser  Permanente  Vaccine  Study"], ["needed  on  the  relative  effectiveness  of  recombinant  vaccines  as  compared  with", "Center, 1 Kaiser Plaza, 17th Fl., Oakland,"], ["", "CA 94612."], ["standard-dose vaccines against influenza-related outcomes in adults under the age", ""], ["of 65 years.", "N Engl J Med 2023;389:2245-55."], ["", "DOI: 10.1056/NEJMoa2302099"], ["", "Copyright \u00a9 2023 Massachusetts Medical Society."], ["METHODS", ""], ["In this cluster-randomized observational study, Kaiser Permanente Northern Cali-", ""], ["fornia facilities routinely administered either a high-dose recombinant influenza", ""], ["vaccine  (Flublok  Quadrivalent)  or  one  of  two  standard-dose  influenza  vaccines", ""], ["during the 2018\u20132019 and 2019\u20132020 influenza seasons to adults 50 to 64 years", ""], ["of  age  (primary  age  group)  and  18  to  49  years  of  age.  Each  facility  alternated", ""], ["weekly  between  the  two  vaccine  formulations.  The  primary  outcome  was  influ-", ""], ["enza (A or B) confirmed by polymerase-chain-reaction (PCR) testing. Secondary", ""], ["outcomes included influenza A, influenza B, and influenza-related hospitalization", ""], ["outcomes.  We  used  Cox  regression  analysis  to  estimate  the  hazard  ratio  of  the", ""], ["recombinant  vaccine  as  compared  with  the  standard-dose  vaccines  against  each", ""], ["outcome. We calculated the relative vaccine effectiveness as 1 minus the hazard", ""], ["ratio.", ""], ["RESULTS", ""], ["The study population included 1,630,328 vaccinees between the ages of 18 and 64", ""], ["years (632,962 in the recombinant-vaccine group and 997,366 in the standard-dose", ""], ["group).  During  this  study  period,  1386  cases  of  PCR-confirmed  influenza  were", ""], ["diagnosed in the recombinant-vaccine group and 2435 cases in the standard-dose", ""], ["group. Among the participants who were 50 to 64 years of age, 559 participants", ""], ["(2.00  cases  per  1000)  tested  positive  for  influenza  in  the  recombinant-vaccine", ""], ["group as compared with 925 participants (2.34 cases per 1000) in the standard-", ""], ["dose group (relative vaccine effectiveness, 15.3%; 95% confidence interval [CI], 5.9", ""], ["to 23.8; P = 0.002). In the same age group, the relative vaccine effectiveness against", ""], ["influenza A was 15.7% (95% CI, 6.0 to 24.5; P = 0.002). The recombinant vaccine", ""], ["was  not  significantly  more  protective  against  influenza-related  hospitalization", ""], ["than were the standard-dose vaccines.", ""], ["CONCLUSIONS", ""], ["The high-dose recombinant vaccine conferred more protection against PCR-con-", ""], ["firmed influenza than an egg-based standard-dose vaccine among adults between", ""], ["the  ages  of  50  and  64  years.  (Funded  by  Sanofi;  ClinicalTrials.gov  number,", ""], ["NCT03694392.)", ""]]}
{"id": "72b01bc9-e03d-4f00-9012-e845a83baec2", "page": 2, "type": "table", "data": [["", "T h e  n e w   e ng l a n d   j o u r na l   o f  m e dic i n e", ""], ["", "", "broadly represent adults in California regarding"], ["", "Every  year  in  the  United  States,  in-", "racial, ethnic, and socioeconomic characteristics,"], ["", "", "although  the  proportions  of  Hispanic,  Asian,"], ["", "million).1  Influenza  vaccination  is  the  primary", "and multiracial residents are higher than those"], ["", "method for preventing influenza-related illness-", "in  other  U.S.  regions  (Table  S1  in  the  Supple-"], ["A Quick Take", "", ""], ["is available at", "es,2  although  the  vaccine  effectiveness  ranges", "mentary Appendix, available with the full text of"], ["NEJM.org", "from 20% in years in which the vaccine is anti-", "this  article  at  NEJM.org).7  Approximately  10%"], ["", "genically  mismatched  to  the  circulating  viral", "of  the  members  are  covered  by  Medicaid.8  The"], ["", "strain to 40 to 60% in years in which the vaccine", "KPNC  institutional  review  board  approved  the"], ["", "is antigenically well matched.2,3 This large varia-", "study with a waiver of informed consent."], ["", "tion in effectiveness between years suggests that", "Representatives of the study sponsor, Sanofi,"], ["", "more effective vaccines are needed.", "did not have a role in the design or conduct of"], ["", "In traditional quadrivalent standard-dose in-", "the  study  or  in  the  analyses  of  the  data.  The"], ["", "activated  influenza  vaccines  (SD-IIV4),  chicken", "Flublok  Quadrivalent \ninfluenza \nvaccine  was"], ["", "eggs  are  used  to  manufacture  the  inf luenza", "donated  by  Sanofi,  and  the  two  standard-dose"], ["", "virus. Mutations in the hemagglutinin protein", "vaccines  used  during  the  study  seasons  were"], ["", "during  egg-based  manufacturing  can  result  in", "purchased by KPNC. The first author wrote the"], ["", "mismatch between the selected strain and the", "first draft of the manuscript. The authors vouch"], ["", "vaccine strain.4 The Flublok Quadrivalent influ-", "for  the  accuracy  and  completeness  of  the  data"], ["", "enza  vaccine  (RIV4,  Sanofi) \nis  manufactured", "presented and for the fidelity of the study to the"], ["", "without chicken eggs, resulting in a recombinant", "protocol (available at NEJM.org)."], ["", "hemagglutinin protein that is genetically identi-", ""], ["", "cal  to  that  in  the  selected  strain.5  The  vaccine", "Study Design"], ["", "also contains three times the amount of hemag-", "This  was  a  cluster-randomized  observational"], ["", "glutinin  protein  as  standard-dose  vaccines,  an", "study  that  was  designed  to  include  all  KPNC"], ["", "increased  level  that  has  been  correlated  with", "members  between  the  ages  of  18  and  64  years"], ["", "increased protective hemagglutinin antibodies.6", "who  had  received  a  licensed  recombinant  or"], ["", "To  estimate  the  relative  effectiveness  of  the", "standard-dose vaccine as part of routine clinical"], ["", "recombinant vaccine as compared with standard-", "care  during  the  three  influenza  seasons  from"], ["", "dose  vaccines  against  laboratory-confirmed  in-", "2018 to 2021.9 The 2019\u20132020 season was trun-"], ["", "fluenza and influenza-related outcomes, we com-", "cated in March 2020 because of the outbreak of"], ["", "pared  the  two  formulations  of  vaccines  among", "the  coronavirus  disease  2019  pandemic;  data"], ["", "members  of  the  Kaiser  Permanente  Northern", "from  the  2020\u20132021  season  were  subsequently"], ["", "California (KPNC) health care system who were", "excluded  from  the  analyses  because  there  were"], ["", "between 18 and 64 years of age during the two", "too few cases of influenza during the pandemic"], ["", "influenza seasons of 2018\u20132019 and 2019\u20132020.", "to be informative. During the study period, influ-"], ["", "", "enza vaccination coverage was similar to national"], ["", "", "coverage (Table S1). The study excluded unvac-"], ["", "Me thods", ""], ["", "", "cinated patients."], ["", "Study Population and Oversight", "The KPNC system includes seven geographic"], ["", "KPNC is an integrated health care delivery sys-", "regions, each containing 8 to 12 medical facili-"], ["", "tem  with  4.6  million  members,  nearly  65%  of", "ties. In each region, the facilities were assigned"], ["", "whom are adults between the ages of 18 and 64", "to either Block A or Block B to optimize the bal-"], ["", "years. Members receive nearly all their care at", "ance between blocks with respect to facility size"], ["", "system-owned  facilities,  which  includes  259", "(Fig. 1). We randomly assigned Block A to start"], ["", "medical clinics and 21 hospitals. The members\u2019", "with administration of a standard-dose vaccine"], ["", "electronic  medical  records  capture  all  medical", "and Block B to start with administration of the"], ["", "services,  including  inpatient  and  outpatient  di-", "recombinant  vaccine.  Thereafter,  each  facility"], ["", "agnoses, laboratory tests, and vaccinations. The", "alternated  the  administration  of  the  two  vac-"], ["", "KPNC  members  include  approximately  a  third", "cines weekly."], ["", "of  the  population  in  Northern  California  and", "Key  features  of  the  study  design  were  that"]]}
{"id": "06449a51-fa12-4267-b5bf-5dd03154d7fe", "page": 3, "type": "table", "data": [["", "Facility 6", "", "", "Facility 5", ""], ["3. After Block A and Block B were assigned", "Facilities within", "", "", "", ""], ["to SD-IIV4 or RIV4 for the first week of the", "a service area", "Week 1", "Week 2", "Week 3", "Week 4"], ["influenza vaccination season, every facility", "", "", "", "", ""], ["", "Facility 1: Block A", "SD-IIV4", "RIV4", "SD-IIV4", "RIV4"], ["alternated formulations weekly until the", "", "", "", "", ""], ["end of the season. For illustrative purposes,", "", "RIV4", "", "RIV4", ""], ["", "Facility 2: Block B", "", "SD-IIV4", "", "SD-IIV4"], ["only 4 weeks of the schedule are shown.", "", "", "", "", ""], ["", "Facility 3: Block B", "RIV4", "SD-IIV4", "RIV4", "SD-IIV4"], ["", "Facility 4: Block A", "SD-IIV4", "RIV4", "SD-IIV4", "RIV4"], ["", "Facility 5: Block B", "RIV4", "SD-IIV4", "RIV4", "SD-IIV4"], ["", "Facility 6: Block A", "SD-IIV4", "RIV4", "SD-IIV4", "RIV4"], ["", "Facility 7: Block B", "RIV4", "SD-IIV4", "RIV4", "SD-IIV4"], ["", "Facility 8: Block B", "RIV4", "SD-IIV4", "RIV4", "SD-IIV4"], ["", "Facility 9: Block A", "SD-IIV4", "RIV4", "SD-IIV4", "RIV4"]]}
{"id": "7fc1a5dd-9fab-4656-bb22-02ce52cbba0d", "page": 4, "type": "table", "data": [["T h e  n e w   e ng l a n d   j o u r na l   o f  m e dic i n e", ""], ["the  weeks  when  influenza  was  circulating.  Pa-", "isting conditions (cardiovascular disease, respi-"], ["tients were unaware of which vaccine was avail-", "ratory disease, cardiorespiratory disease, obesity,"], ["able at any facility. During the study period, the", "and  diabetes)  in  the  primary  age  group.  Other"], ["facilities  administered  primarily  high-dose  vac-", "estimates  of  relative  vaccine  effectiveness  were"], ["cines  to  adults  who  were  65  years  of  age  or", "considered to be exploratory."], ["older, which made it infeasible to include those", ""], ["members in the study randomization.", "Statistical Analysis"], ["", "We tested the null hypotheses that the recombi-"], ["Outcomes", "nant vaccine would not be any more or any less"], ["The  primary  outcome  was  influenza  as  con-", "effective  than  a  standard-dose  vaccine  against"], ["firmed by polymerase-chain-reaction (PCR) test-", "influenza, using a two-sided test with a P value"], ["ing  (Cepheid  GeneXpert  PCR  assay,  a  test  that", "of  less  than  0.05  indicating  statistical  signifi-"], ["also identifies respiratory syncytial virus [RSV]).", "cance. We estimated that the administration of"], ["Physicians at each facility ordered influenza PCR", "400,000 doses each of the two vaccine formula-"], ["tests at their discretion on the basis of clinical", "tions to patients between the ages of 18 and 64"], ["presentation; rapid influenza antigen testing was", "years  each  influenza  season  would  provide  the"], ["not performed.", "study with 86% power to detect a relative vaccine"], ["Secondary outcomes were PCR-confirmed in-", "effectiveness  of  10.0%  against  PCR-confirmed"], ["fluenza A, PCR-confirmed influenza B, and hos-", "influenza. On the basis of previous data, we es-"], ["pitalization  for  PCR-confirmed  influenza,  for", "timated  the  occurrence  of  2.18  PCR-confirmed"], ["community-acquired pneumonia, and for cardio-", "influenza  cases  per  1000  participants  in  the"], ["respiratory events including community-acquired", "standard-dose group."], ["pneumonia.  We  identified  community-acquired", "We used Cox regression analysis to estimate"], ["pneumonia  and  other  cardiorespiratory  events", "the adjusted hazard ratio and 95% confidence"], ["using primary discharge diagnosis codes as listed", "intervals  for  the  recombinant  vaccine  as  com-"], ["in the International Classification of Diseases, 10th", "pared  with  a  standard-dose  vaccine  for  each"], ["Revision (ICD-10) (Table S2).", "outcome.  The  model  specified  a  calendar  time"], ["Exploratory outcomes were an influenza diag-", "scale and included adjustments for sex, race or"], ["nosis  (PCR-confirmed  or  clinically  diagnosed", "ethnic group, and age and an age-squared factor"], ["influenza on the basis of ICD-10 codes), nonelec-", "(in case age and risk had either a linear or cur-"], ["tive  hospitalization  for  any  cause,  and  death", "vilinear  association).  Risk  sets  were  formed  on"], ["from any cause. For each outcome except death", "each date on which at least one outcome event"], ["from any cause, we counted only the first event", "occurred  in  either  study  group.  Each  risk  set"], ["during each season that occurred more than 14", "contained every participant in follow-up on that"], ["days after vaccination. All deaths after vaccina-", "calendar date. Most of the participants had been"], ["tion within the study period were considered to", "vaccinated before the beginning of the influenza"], ["be a safety outcome and were counted even if they", "season  and  were  included  in  every  risk  set"], ["had occurred within 14 days after vaccination.", "throughout the season."], ["", "The  Cox  model  also  used  stabilized  weights"], ["Objectives", "that were based on propensity scores. The statis-"], ["The primary objective was to estimate the rela-", "tical  analysis  plan  prespecified  the  use  of  pro-"], ["tive vaccine effectiveness of the recombinant vac-", "pensity scores if imbalances were found in any"], ["cine as compared with a standard-dose vaccine", "study variables. We observed modest imbalances"], ["against PCR-confirmed influenza in patients be-", "at some facilities in one or both seasons, although"], ["tween the ages of 50 and 64 years, the primary", "not overall (Tables S4 and S5). Thus, we created"], ["age  group  (Table  S3).  The  secondary  objectives", "propensity scores that were specific for each fa-"], ["were  to  estimate  the  relative  vaccine  effective-", "cility  and  season.  The  propensity  scores  were"], ["ness of the recombinant vaccine against second-", "derived  by  logistic  regression  to  estimate  the"], ["ary  outcomes  in  patients  in  the  primary  age", "probability of the receipt of a recombinant vac-"], ["group and against secondary outcomes in five", "cine  rather  than  a  standard-dose  vaccine  with"], ["prespecified  subgroups  of  patients  with  preex-", "respect  to  sex,  race,  age,  coexisting  illnesses,"]]}
{"id": "3a9f38df-baa4-4efd-af0c-02ac4036a182", "page": 5, "type": "table", "data": [["Recombinant or Standard-Dose Influenza Vaccine", ""], ["indicators of health care\u2013seeking behavior (e.g.,", "ments  of  the  recombinant  vaccine  occasionally"], ["previous  influenza  vaccination),  2-month  inter-", "left  some  clinics  temporarily  without  enough"], ["vals of calendar time, and other factors. Missing", "recombinant vaccine to comply with the week-"], ["data were not imputed.", "ly  schedule,  so  standard-dose  vaccines  were"], ["The  relative  vaccine  effectiveness  was  based", "then administered to prevent interruptions in"], ["on the hazard ratio (1 minus the hazard ratio,", "patient care."], ["expressed as a percentage). This calculation es-", "Among the 675,252 patients between 50 and"], ["timated the percent reduction in the incidence of", "64  years  of  age,  279,400  (41.4%)  received  the"], ["the  outcome  in  the  recombinant-vaccine  group", "recombinant  vaccine  and  395,852  (58.6%)  re-"], ["as  compared  with  that  in  the  standard-dose", "ceived a standard-dose vaccine (Table 1). Among"], ["group. The proportional-hazards assumption of", "the 955,076 patients between 18 and 49 years of"], ["the Cox regression was evaluated, and no viola-", "age,  353,562  (37.0%)  received  the  recombinant"], ["tion was found (Fig. S1).", "vaccine and 601,514 (63.0%) received a standard-"], ["For  secondary  objectives  in  participants  be-", "dose vaccine (Table S6)."], ["tween the ages of 50 and 64 years, we adjusted", "Of the 16,340 influenza PCR tests performed"], ["for  multiplicity  by  Holm\u2019s  method.10  Subgroup", "in  the  study  population,  3821  (23.4%)  were  in-"], ["analyses involving participants with preexisting", "fluenza  positive.  Of  the  PCR-confirmed  influ-"], ["conditions were not adjusted for multiplicity. We", "enza cases, 1484 (38.8%) were diagnosed in pa-"], ["conducted sensitivity analyses in which we used", "tients between the ages of 50 and 64 years and"], ["propensity scores in alternative ways, used a robust", "2337 (61.2%) in patients between the ages of 18"], ["variance estimator, stratified risk sets according", "and 49 years. Among the participants with PCR-"], ["to  facility  and  vaccination  week,  and  specified", "confirmed  influenza,  hospitalization  occurred"], ["age as a spline (see the Supplementary Methods", "in 248 of 1484 participants (16.7%) among those"], ["section).", "between the ages of 50 and 64 years and in 136"], ["To  assess  possible  residual  confounding,  we", "of 2337 (5.8%) of those between the ages of 18"], ["examined  PCR-confirmed  RSV  infection  as  a", "and 49 years."], ["negative control outcome because we would not", "The demographic characteristics of the par-"], ["expect influenza vaccination to be associated with", "ticipants at baseline were similar in the two vac-"], ["a reduction in this infection. A nontrivial asso-", "cine groups and in the two age groups (Table 1"], ["ciation between receipt of the recombinant vac-", "and Table S6). There was some variation in the"], ["cine  and  RSV  infection  would  suggest  bias  in", "timing of the administration of the two vaccines"], ["our estimate of the relative vaccine effectiveness", "according to geographic region, although during"], ["against  influenza.  Conversely,  a  finding  of  no", "the  two  influenza  seasons,  most  vaccinations"], ["association between receipt of the recombinant", "in the two groups had occurred by mid-to-late"], ["vaccine and RSV infection would be reassuring", "November (Tables S4 and S5)."], ["that  our  estimates  of  relative  vaccine  effective-", ""], ["ness were not biased by unmeasured factors that", "Primary and Secondary Analyses"], ["might  affect  the  risk  of  both  laboratory-con-", "In patients between the ages of 50 and 64 years,"], ["firmed  RSV  infection  and  influenza.  All  data", "559 (2.00 cases per 1000) tested positive for in-"], ["analyses  were  performed  with  the  use  of  SAS", "fluenza \nin \nthe  recombinant-vaccine  group  as"], ["software, version 9.4 (SAS Institute).", "compared with 925 (2.34 per 1000) in the stan-"], ["", "dard-dose group (Table 2). For the primary ob-"], ["", "jective,  the  relative  vaccine  effectiveness  of  the"], ["R e sult s", ""], ["", "recombinant vaccine as compared with standard-"], ["Study Participants", "dose  vaccines  against  all  PCR-confirmed  influ-"], ["The study population included 1,630,328 partici-", "enza was 15.3% (95% CI, 5.9 to 23.8; P = 0.002)."], ["pants during influenza seasons in 2018\u20132019 and", "The estimate of relative vaccine effectiveness"], ["2019\u20132020. Of these participants, 632,962 (38.8%)", "for  the  secondary  objective  of  PCR-confirmed"], ["received  the  recombinant  vaccine  and  997,366", "influenza  A  was  15.7%  (95%  CI,  6.0  to  24.5;"], ["(61.2%) received a standard-dose vaccine (Fig. 2", "P = 0.002;  the  P  value  was  below  Holm\u2019s  multi-"], ["and Table S6). In both seasons, delays in ship-", "plicity-adjusted  threshold  of  an  alpha  level  of"]]}
{"id": "473fc41e-9d0f-41e5-be7e-f58c36479efa", "page": 6, "type": "table", "data": [["", "632,962 Were included in the final cohort", "997,366 Were included in the final cohort"], ["", "353,562 Were 18\u201349 yr of age", "601,514 Were 18\u201349 yr of age"], ["", "279,400 Were 50\u201364 yr of age", "395,852 Were 50\u201364 yr of age"], ["Figure 2. Vaccinated Adults in the Study Population (2018\u20132021).", "", ""], ["Shown is the final cohort of study participants between 18 and 64 years of age after the application of exclusion criteria. Patients who", "", ""], ["were vaccinated as inpatients were excluded from the study because such influenza vaccinations could not be included in the random-", "", ""], ["ization. The eligible date ranges for influenza vaccinations were September 17, 2018, to April 21, 2019; September 3, 2019, to February", "", ""], ["25, 2020; and August 31, 2020, to April 8, 2021. In some cases, data were excluded from the analyses because records did not indicate", "", ""], ["the location of the facility where the vaccine had been administered. Propensity scores were derived by logistic regression to estimate", "", ""], ["the probability of the receipt of a recombinant vaccine rather than a standard-dose vaccine with respect to sex, race, age, coexisting ill-", "", ""], ["nesses, indicators of health care\u2013seeking behavior, 2-month intervals of calendar time, and other factors. Some patients were vaccinated at", "", ""], ["facilities where the data were too sparse to generate a facility-specific propensity score. Data for the third influenza season (2020\u20132021)", "", ""], ["were not included in the study because of virtually no circulation of influenza virus during the first year of the coronavirus disease 2019", "", ""], ["pandemic.", "", ""]]}
{"id": "37455f8b-30c5-48e7-a0db-8eb420e6e63f", "page": 7, "type": "table", "data": [["Characteristic", "(N = 279,400)", "(N = 395,852)", "(N = 675,252)"], ["", "", "no. of participants (%)", ""], ["Sex \u2014 no. (%)", "", "", ""], ["Male", "124,540 (45)", "175,600 (44)", "300,140 (44)"], ["Female", "154,860 (55)", "220,252 (56)", "375,112 (56)"], ["Race or ethnic group \u2014 no. (%)\u2020", "", "", ""], ["White", "142,757 (51)", "198,434 (50)", "341,191 (51)"], ["Black", "13,693 (5)", "20,814 (5)", "34,507 (5)"], ["Asian", "58,416 (21)", "84,154 (21)", "142,570 (21)"], ["Pacific Islander", "1,686 (1)", "2,363 (1)", "4,049 (1)"], ["Native American", "1,268 (<1)", "1,836 (<1)", "3,104 (<1)"], ["Multiracial", "7,299 (3)", "10,908 (3)", "18,207 (3)"], ["Unknown or other", "54,281 (19)", "77,343 (20)", "131,624 (19)"], ["Hispanic ethnic group \u2014 no. (%)\u2020", "", "", ""], ["Yes", "46,318 (17)", "65,868 (17)", "112,186 (17)"], ["No or unknown", "233,082 (83)", "329,984 (83)", "563,066 (83)"], ["Coexisting illness \u2014 no. (%)", "", "", ""], ["Asthma", "39,909 (14)", "56,398 (14)", "96,307 (14)"], ["Diabetes", "49,506 (18)", "69,924 (18)", "119,430 (18)"], ["Chronic obstructive pulmonary disease", "5,628 (2)", "7,729 (2)", "13,357 (2)"], ["Coronary heart disease", "10,613 (4)", "14,883 (4)", "25,496 (4)"], ["Receipt of influenza vaccine in previous year", "", "", ""], ["Yes", "207,236 (74)", "290,370 (73)", "497,606 (74)"], ["No", "72,164 (26)", "105,482 (27)", "177,646 (26)"]]}
{"id": "2c7fccf3-2598-48c5-a436-84c9b8144127", "page": 7, "type": "table", "data": [["Receipt of influenza vaccine in previous year", ""], ["Yes\n207,236 (74)", "290,370 (73)\n497,606 (74)"], ["No\n72,164 (26)", "105,482 (27)\n177,646 (26)"], ["*  Additional details regarding the demographic and clinical characteristics of the participants in this age group, for those", ""], ["in the younger age group (18 to 49 years), and for the entire study population (18 to 64 years of age) are provided in", ""], ["Table S6 in the Supplementary Appendix.", ""], ["\u2020  Race or ethnic group was reported by the participants.", ""], ["0.01) (Table 2). For outcomes involving hospital-", "measure  of  relative  vaccine  effectiveness  that"], ["ization,  the  recombinant  vaccine  was  not  sig-", "significantly  differed  from  zero  was  against"], ["nificantly more effective than the standard-dose", "PCR-confirmed  inf luenza  B  in  the  subgroup"], ["vaccines, although the point estimate was 15.9%", "with  respiratory  conditions  (relative  vaccine  ef-"], ["for hospitalization for PCR-confirmed influenza", "fectiveness,  78.2%;  95%  CI,  3.1  to  95.1)  (Table"], ["and  16.7%  for  hospitalization  for  community-", "S7). In post hoc analyses among participants in"], ["acquired pneumonia (Table 2). Post hoc analysis", "the  same  age  subgroup  with  any  of  the  pre-"], ["of these two hospitalization outcomes combined", "specified  preexisting  conditions,  measures  of"], ["yielded an estimate for relative vaccine effective-", "relative  vaccine  effectiveness  were  14.3%  (95%"], ["ness of 19.7% (95% CI, 2.8 to 33.7).", "CI, 2.4 to 24.8) for PCR-confirmed influenza and"], ["", "14.9% (95% CI, 2.6 to 25.7) for influenza A in-"], ["Subgroup and Exploratory Analyses", "fection (Fig. 3 and Table S7)."], ["In subgroup analyses among participants in the", "Among participants in the younger age group"], ["older age group (50 to 64 years) with any of the", "(18 to 49 years), 827 (2.34 cases per 1000) tested"], ["five prespecified preexisting conditions, the only", "positive  for  influenza  in  the  recombinant-vac-"]]}
{"id": "34da2e32-6df3-4c3e-b0f7-8a2bf6b30fdb", "page": 8, "type": "table", "data": [["", "", "T h e  n e w   e ng l a n d   j o u r na l   o f  m e dic i n e", "", "", "", ""], ["", "Table 2. Primary and Secondary Outcomes and Relative Vaccine Effectiveness among Participants 50 to 64 Years of Age.*", "", "", "", "", ""], ["", "Recombinant", "Standard-Dose", "", "Adjusted", "Relative Vaccine", ""], ["", "Vaccine", "Vaccine", "Unadjusted", "Hazard Ratio", "Effectiveness", ""], ["Outcome", "(N = 279,400)", "(N = 395,852)", "Rate Ratio", "(95% CI)\u2020", "(95% CI)", "P Value\u2021"], ["", "no. of cases per 1000", "", "", "", "%", ""], ["Primary outcome", "", "", "", "", "", ""], ["PCR-confirmed influenza", "559 (2.00)", "925 (2.34)", "0.86", "0.85 (0.76 to 0.94)", "15.3 (5.9 to 23.8)", "0.002"], ["Secondary outcomes", "", "", "", "", "", ""], ["PCR-confirmed influenza A", "522 (1.87)", "862 (2.18)", "0.86", "0.84 (0.76 to 0.94)", "15.7 (6.0 to 24.5)", "0.002"], ["PCR-confirmed influenza B", "37 (0.13)", "64 (0.16)", "0.82", "0.90 (0.60 to 1.34)", "10.3 (\u221233.9 to 39.9)", "0.59"], ["Hospitalization for PCR-", "95 (0.34)", "153 (0.39)", "0.88", "0.84 (0.65 to 1.09)", "15.9 (\u22129.2 to 35.2)", "0.19"], ["confirmed influenza", "", "", "", "", "", ""], ["Hospitalization for community-", "106 (0.38)", "183 (0.46)", "0.82", "0.83 (0.66 to 1.06)", "16.7 (\u22125.6 to 34.4)", "0.13"], ["acquired pneumonia", "", "", "", "", "", ""], ["Hospitalization for cardiorespira-", "631 (2.26)", "890 (2.25)", "1.004", "0.98 (0.88 to 1.08)", "2.4 (\u22128.1 to 11.9)", "0.64"], ["tory event", "", "", "", "", "", ""], ["*  PCR denotes polymerase chain reaction.", "", "", "", "", "", ""], ["\u2020  Models were adjusted for age, age squared, sex, and race or ethnic group after weighting with stabilized facility-specific propensity scores.", "", "", "", "", "", ""], ["", "In post hoc sensitivity analyses, models were further adjusted for potential clustering according to facility and yielded results similar to", "", "", "", "", ""], ["those listed here. Details are provided in Table S13.", "", "", "", "", "", ""], ["\u2021  Adjustment for multiplicity for the secondary outcomes was performed with the use of Holm\u2019s adjustment method. The P values that were", "", "", "", "", "", ""], ["", "obtained for the five secondary outcomes were rank-ordered and compared with corresponding adjusted nominal alpha values of 0.01, 0.0125,", "", "", "", "", ""], ["0.0167, 0.025, and 0.05.", "", "", "", "", "", ""]]}
{"id": "9323c93b-e8eb-42ba-92f8-c6a3bf3584d2", "page": 8, "type": "table", "data": [["\u2021  Adjustment for multiplicity for the secondary outcomes was performed with the use of Holm\u2019s adjustment method. The P values that were", ""], ["obtained for the five secondary outcomes were rank-ordered and compared with corresponding adjusted nominal alpha values of 0.01, 0.0125,", ""], ["cine group as compared with 1510 participants", "S11). For the outcome of PCR-confirmed influ-"], ["(2.51 cases per 1000) in the standard-dose group", "enza  among  patients  in  the  older  age  group,"], ["(Table S8). For three exploratory objectives in this", "relative vaccine effectiveness was 14.4% (95% CI,"], ["age group, the relative vaccine effectiveness was", "\u22121.1 to 27.5) during 2018\u20132019 and 16.1% (95%"], ["10.2% (95% CI, 1.4 to 18.2) against influenza A,", "CI, 3.7 to 26.9) during 2019\u20132020."], ["10.8%  (95%  CI,  6.6  to  14.7)  against  diagnosed", "For  both  the  PCR-confirmed  influenza  and"], ["influenza,  and  19.5%  (95%  CI,  5.4  to  31.5)", "hospitalization outcomes, the results of sensitiv-"], ["against  influenza  A  in  the  subgroup  with  obe-", "ity analyses were consistent with findings in the"], ["sity (Tables S7 and S8).", "primary analyses (Tables S12 and S13). The esti-"], ["In  the  younger  age  group,  the  only  explor-", "mates of relative vaccine effectiveness from the"], ["atory objective for which the relative vaccine ef-", "RSV-negative  control  analyses  did  not  differ"], ["fectiveness  was  significantly  below  zero  was", "from zero (Table S14)."], ["death from any cause (\u221245.5; 95% CI, \u2212100.2 to", ""], ["\u22125.8) (Table S8). During the two influenza sea-", ""], ["", "Discussion"], ["sons, there were 145 deaths: 66 in the recombi-", ""], ["nant-vaccine group and 79 in the standard-dose", "In this real-world study, we evaluated the effec-"], ["group; most of these deaths occurred at least 61", "tiveness of a high-dose recombinant vaccine as"], ["days after vaccination. The most common causes", "compared with an egg-based standard-dose vac-"], ["of death in both study groups were cancer, ac-", "cine among more than 1.6 million adults during"], ["cidents,  homicide,  suicide,  and  cardiovascular", "two  influenza  seasons.  In  our  analysis  of  the"], ["events (Table S9). Causes of death as assessed by", "primary  outcome  in  older  patients  between  50"], ["chart review were not considered by the investi-", "and 64 years of age, the incidence of PCR-con-"], ["gators to be related to either influenza or influ-", "firmed influenza was 15.3% lower among those"], ["enza vaccination.", "who  received \nthe  recombinant  vaccine \nthan"], ["Single-season estimates of relative vaccine ef-", "among those who received a standard-dose vac-"], ["fectiveness  were  generally  consistent  with  the", "cine, a finding that rejected the null hypothesis."], ["combined two-season estimates (Tables S10 and", "The evidence that the recombinant vaccine con-"]]}
{"id": "ff846870-c0cb-4eb4-ac8a-03dce3795c43", "page": 9, "type": "table", "data": [["Subgroup", "", ""], ["PCR-confirmed influenza", "", ""], ["Cardiovascular disease", "", ""], ["Respiratory disease", "", ""], ["Cardiorespiratory disease", "", ""], ["Obesity", "", ""], ["Diabetes", "", ""], ["Any of the above conditions", "", ""], ["Hospitalization for PCR-confirmed influenza", "", ""], ["Cardiovascular disease", "", ""], ["Respiratory disease", "", ""], ["Cardiorespiratory disease", "", ""], ["Obesity", "", ""], ["Diabetes", "", ""], ["Any of the above conditions", "", ""], ["", "Hospitalization for community-acquired pneumonia", ""], ["Cardiovascular disease", "", ""], ["Respiratory disease", "", ""], ["Cardiorespiratory disease", "", ""], ["Obesity", "", ""], ["Diabetes", "", ""], ["Any of the above conditions", "", ""], ["", "\u221250", "\u221245"]]}
{"id": "35e80a74-0aed-4cb3-b2f6-037f7f71fd52", "page": 9, "type": "table", "data": [["\u221250", "\u221245", "\u221240", "\u221235", "\u221230", "\u221225", "\u221220", "\u221215", "\u221210", "\u22125", "0", "5", "10", "15", "20", "25", "30", "35", "40", "45", "50", "55"], ["", "", "", "", "", "", "", "", "", "", "Percentage", "", "", "", "", "", "", "", "", "", "", ""], ["Figure 3. Subgroup Analysis of Relative Vaccine Effectiveness against Influenza among Participants between 50", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", ""], ["and 64 Years of Age, According to Preexisting Conditions.", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", ""], ["Shown is a forest plot of the relative effectiveness of the recombinant vaccine as compared with a standard-dose", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", ""], ["vaccine against influenza as confirmed by polymerase-chain-reaction (PCR) assay, hospitalization for PCR-confirmed", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", ""], ["influenza, and hospitalization for community-acquired pneumonia among study participants in the older age group,", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", ""], ["according to the presence of five prespecified preexisting conditions.", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", ""]]}
{"id": "503579ac-b0f0-4499-bd42-4f212ee4b780", "page": 9, "type": "table", "data": [["", "influenza, and hospitalization for community-acquired pneumonia among study participants in the older age group,"], ["according to the presence of five prespecified preexisting conditions.", ""], ["ferred  more  protection  against  influenza  than", "nant-vaccine  group  than  in  the  standard-dose"], ["standard-dose vaccines was strengthened by our", "group (relative vaccine effectiveness, 10.8%; 95%"], ["cluster-randomized study design.", "CI, 6.6 to 14.7). For PCR-confirmed influenza A,"], ["In  secondary  analyses  involving  the  same", "the incidence was similarly lower in the recom-"], ["older age group, the incidence of PCR-confirmed", "binant-vaccine  group  (relative  vaccine  effective-"], ["influenza A was 15.7% lower in the recombinant-", "ness,  10.2;  95%  CI,  1.4  to  18.2).  For  5  of  the"], ["vaccine group than in the standard-dose group", "other 10 exploratory analyses (2 of which were"], ["(P = 0.002). Our analyses of the three additional", "performed  in  participants  between  50  and  64"], ["secondary outcomes in this age group suggested", "years  of  age),  the  estimated  relative  vaccine  ef-"], ["that  the  recombinant  vaccine  may  confer  more", "fectiveness was in the range of 1 to 10% with"], ["protection  than  standard-dose  vaccines  against", "95% confidence intervals overlapping 0%. The"], ["hospitalization outcomes. Although these find-", "remaining  5  exploratory  analyses  (1  of  which"], ["ings  were  not  significant,  a  post  hoc  analysis", "was  performed  in  participants  between  50  and"], ["combining  hospitalization  for  PCR-confirmed", "64  years  of  age)  yielded  negative  estimates  for"], ["influenza  and  hospitalization  for  community-", "relative vaccine effectiveness, including the anal-"], ["acquired  pneumonia  yielded  a  relative  vaccine", "ysis of death from any cause among participants"], ["effectiveness of 19.7% (95% CI, 2.8 to 33.7).", "between 18 and 49 years of age (relative vaccine"], ["The  12  exploratory  analyses  yielded  some-", "effectiveness,  \u221245.5;  95%  CI,  \u2212100.2  to  \u22125.8)."], ["what inconsistent results. For influenza diagno-", "Chart reviews of all 145 deaths in this age group"], ["ses  overall  (including  unconfirmed  diagnoses)", "did  not  suggest  that  the  recombinant  vaccine"], ["among patients between the ages of 18 and 49", "caused any deaths or that standard-dose vaccines"], ["years,  the  incidence  was  lower  in  the  recombi-", "prevented  more  deaths  than  the  recombinant"]]}
{"id": "63d9462e-d5b8-4f34-8093-9139310b1e36", "page": 10, "type": "table", "data": [["T h e  n e w   e ng l a n d   j o u r na l   o f  m e dic i n e", ""], ["vaccine.  Mortality  in  both  groups  of  vaccinees", "health  care\u2013seeking  behavior,  and  the  number"], ["was  substantially  lower  than  population-wide", "of  weeks  since  vaccination.  To  our  knowledge,"], ["mortality at KPNC and nationwide in a similar", "this design has not been previously used, and its"], ["age group.11,12", "handling of potential confounding bias has not"], ["If  standard-dose  vaccines  were  already  pre-", "been formally studied. Our intent was to mini-"], ["venting  most  cases  of  influenza  and  break-", "mize imbalances between the participants who"], ["through cases were uncommon, preventing 15%", "received each vaccine, both within and between"], ["of breakthrough cases would be of modest pub-", "facilities.  We  also  included  several  sensitivity"], ["lic health benefit. However, since standard-dose", "analyses  to  address  potential  biases  from  clus-"], ["vaccines prevent at most 40 to 60% of influenza", "tering  according  to  facility.  Sensitivity  analyses"], ["cases annually,13 reducing the incidence of break-", "that  were  stratified  either  according  to  facility"], ["through influenza by 15% would provide a sub-", "(to  compare  within  facilities)  or  according  to"], ["stantial public health benefit, especially during", "week  (to  compare  between  facilities)  showed  a"], ["more severe influenza seasons.", "relative  vaccine  effectiveness  of  approximately"], ["Several  studies  have  shown  benefit  for  the", "15%,  similar  to  the  findings  of  our  primary"], ["recombinant vaccine and other high-dose influ-", "analysis."], ["enza  vaccines  as  compared  with  standard-dose", "Our study also has several limitations. First,"], ["vaccines  in  adults  who  are  65  years  of  age  or", "in our real-world setting, compliance with the"], ["older,  findings  that  have  been  attributed  to  an", "weekly  assigned  vaccine  schedule  occasionally"], ["improved immune response.5,14-17 In the current", "varied because of logistic constraints, including"], ["study,  we  compared  the  effectiveness  of  the", "supply-chain issues for the recombinant vaccine,"], ["high-dose  recombinant  vaccine  with \nthat  of", "which led to different numbers of participants in"], ["standard-dose vaccines in patients between the", "the two groups. Second, our data were limited to"], ["ages  of  18  and  64  years.  The  effectiveness  of", "two influenza seasons; relative vaccine effective-"], ["standard-dose vaccines \u2014 especially against the", "ness may vary across seasons, depending on the"], ["influenza A H3N2 subtype \u2014 may be attenuated", "vaccine  match  with  circulating  strains.  Third,"], ["by antigenic drift during egg-based manufactur-", "our primary outcome did not include infections"], ["ing,  whereas  the  recombinant  vaccine  is  not", "in  persons  who  did  not  undergo  PCR  testing,"], ["susceptible to such drift. However, data from the", "which limits its generalizability. Fourth, the study"], ["California Department of Public Health showed", "had  limited  power  to  detect  a  clinically  mean-"], ["that the H3N2 strain circulated only during the", "ingful  benefit  of  the  recombinant  vaccine  as"], ["second half of the 2018\u20132019 season,18 and even", "compared  with  a  standard-dose  vaccine  with"], ["then, the circulating strain had drifted such that", "respect to less frequent outcomes, such as hos-"], ["it was poorly matched to both the recombinant", "pitalization for PCR-confirmed influenza. Finally,"], ["vaccine and the standard-dose vaccines.19,20 Dur-", "although KPNC has a diverse population, it may"], ["ing our study period, the observed benefit of the", "not be representative of other populations in the"], ["recombinant  vaccine  as  compared  with  a  stan-", "United States."], ["dard-dose vaccine seems less likely due to higher", "In this study performed during two influenza"], ["relative vaccine effectiveness against H3N2 than", "seasons, participants between the ages of 50 and"], ["to higher effectiveness against influenza A over-", "64 years who received the recombinant vaccine"], ["all associated with its higher dose of hemagglu-", "had more protection against confirmed influenza"], ["tinin antigen.", "than those who received a standard-dose vaccine."], ["A strength of our study is that the two study", ""], ["", "Supported by Sanofi."], ["vaccine  formulations  were  alternated  in  weekly", ""], ["", "Disclosure forms provided by the authors are available with"], ["intervals of time at each facility, which allowed", "the full text of this article at NEJM.org."], ["", "We thank many groups within Kaiser Permanente Northern"], ["us to balance covariates of interest as designed.", ""], ["", "California for their dedication and contributions to this study,"], ["In every KPNC geographic area, when influenza", ""], ["", "including the members of the KPNC Seasonal Flu Program, the"], ["arrived, there were already participants who had", "clinical teams who managed and administered influenza vac-"], ["", "cines, the pharmacy teams, and the KPNC regional laboratory,"], ["received one of the two formulations of vaccine", ""], ["", "without whose support this study would not have been possible;"], ["and  who  were  similar  with  respect  to  demo-", ""], ["", "and Ruvim Izikson of Sanofi for scientific discussions and co-"], ["graphic  characteristics,  coexisting \nillnesses,", "ordination."]]}
{"id": "0f52ef82-fe79-4415-873d-39dc7a58e5fa", "page": 11, "type": "table", "data": [["", "Recombinant or Standard-Dose Influenza Vaccine", ""], ["References", "", ""], ["1.  Centers for Disease Control and Preven-", "ser  Permanente  members  to  the  general", "spotlights/  2021 - 2022/  specific - vaccines"], ["tion. Disease burden of flu (https://www", "population: implications for generalizabil-", "- seniors . htm)."], [". cdc . gov/  flu/  about/  burden/  index . html).", "ity of research. Perm J 2023; 27: 87-98.", "16.  Grohskopf LA, Blanton LH, Ferdinands"], ["2.  Centers for Disease Control and Pre-", "9. \nClinicalTrials.gov. Flublok v. standard", "JM, et al. Prevention and control of sea-"], ["vention.  Seasonal  flu  vaccines  (https://", "dose vaccine effectiveness among Kaiser", "sonal \ninfluenza  with  vaccines:  recom-"], ["www . cdc . gov/  flu/  prevent/  flushot . htm).", "Permanente Northern California adults", "mendations  of  the  Advisory  Committee"], ["3. \nCenters for Disease Control and Pre-", "18-64 Years (https://clinicaltrials . gov/  ct2/", "on \nImmunization  Practices  \u2014  United"], ["vention.  Vaccine  effectiveness:  how  well", "show/  NCT03694392).", "States, 2022\u201323 influenza season. MMWR"], ["do f lu vaccines work? (https://www . cdc", "10.  Food and Drug Administration. Mul-", "Recomm Rep 2022; 71: 1-28."], [". gov/  f lu/  vaccines - work/  vaccineeffect", "tiple endpoints in clinical trials: guidance", "17.  Dawood FS, Naleway AL, Flannery B,"], [". htm).", "for industry. October 2022 (https://www", "et al. Comparison of the immunogenicity"], ["4.  Wu NC, Lv H, Thompson AJ, et al. Pre-", ". fda . gov/  regulatory - information/  search - fda", "of  cell  culture-based  and  recombinant"], ["venting an antigenically disruptive muta-", "- guidance - documents/  multiple - endpoints", "quadrivalent influenza vaccines to conven-"], ["tion in egg-based H3N2 seasonal influen-", "- clinical - trials - guidance - industry).", "tional  egg-based  quadrivalent  influenza"], ["za vaccines by mutational incompatibility.", "11.  Kochanek KD, Xu J, Arias E. Mortality", "vaccines among healthcare personnel aged"], ["Cell Host Microbe 2019; 25(6): 836.e5-844.e5.", "in  the  United  States,  2019.  NCHS  Data", "18-64 years: a randomized open-label trial."], ["5.  Dunkle  LM,  Izikson  R,  Patriarca  P,", "Brief 2020; 395: 1-8.", "Clin Infect Dis 2021; 73: 1973-81."], ["et al. Efficacy of recombinant influenza", "12.  Sidney S, Sorel ME, Quesenberry CP,", "18.  California  Department \nof \nPublic"], ["vaccine in adults 50 years of age or older.", "et al. Comparative trends in heart disease,", "Health. \nInfluenza  surveillance \nreport,"], ["N Engl J Med 2017; 376: 2427-36.", "stroke,  and  all-cause  mortality  in  the", "2018\u20132019 season. December 2019 (https://"], ["6.  Krammer F. The human antibody re-", "United States and a large integrated health-", "www . cdph . ca . gov/  Programs/  CID/  DCDC/"], ["sponse to influenza A virus infection and", "care delivery system. Am J Med 2018; 131(7):", "CDPH%20Document%20Library/"], ["vaccination.  Nat  Rev  Immunol  2019; 19:", "829.e1-836.e1.", "Immunization/  Annual2018 - 19 . pdf)."], ["383-97.", "13.  Centers for Disease Control and Preven-", "19.  Flannery  B,  Kondor  RJG,  Chung  JR,"], ["7.  Gordon NP. Similarity of adult Kaiser", "tion. Past seasons\u2019 vaccine effectiveness es-", "et al. Spread of antigenically drifted influ-"], ["Permanente members to the adult popula-", "timates (https://www . cdc . gov/  flu/  vaccines", "enza A(H3N2) viruses and vaccine effec-"], ["tion in Kaiser Permanente\u2019s northern Cali-", "- work/  past - seasons - estimates . html).", "tiveness  in  the  United  States  during  the"], ["fornia service area: comparisons based on", "14.  Dunkle LM, Izikson R. Recombinant", "2018-2019 season. J Infect Dis 2020; 221: 8-15."], ["the  2017/2018  cycle  of \nthe  California", "hemagglutinin influenza vaccine provides", "20.  Wang W, Alvarado-Facundo E, Vassell"], ["Health  Interview  Survey,  Oakland,  CA:", "broader spectrum protection. Expert Rev", "R, et al. Comparison of A(H3N2) neutral-"], ["Kaiser  Permanente  Northern  California", "Vaccines 2016; 15: 957-66.", "izing antibody responses elicited by 2018-"], ["Division of Research, November 8, 2020", "15.  Centers for Disease Control and Pre-", "2019 season quadrivalent inf luenza vac-"], ["(https://memberhealthsurvey . kaiser . org/", "vention. ACIP flu meeting update: flu vac-", "cines  derived \nfrom  eggs, \ncells,  and"], ["resources/  chis).", "cines worked better than reported & ACIP", "recombinant  hemagglutinin.  Clin  Infect"], ["8.  Davis  AC,  Voelkel  JL,  Remmers  CL,", "recommends specific vaccines for seniors.", "Dis 2021; 73(11): e4312-e4320."], ["Adams JL, McGlynn EA. Comparing Kai-", "June 23, 2022 (https://www . cdc . gov/  f lu/", "Copyright \u00a9 2023 Massachusetts Medical Society."]]}
